Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833474 | 0.93 | ALDH1A1 (0.53) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL7110609 | 0.85 | HSD17B10 (0.52) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL13986557 | 0.84 | SMN1; SMN2 (0.52) | LMNAMAPTKMT2ARAB9APOLB | |
| SCHEMBL22013863 | 0.82 | MAPT (0.50) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL16713302 | 0.82 | CYP1A2 (0.50) | ALDH1A1MAPTKMT2ARAB9APOLB | |
| SCHEMBL4842029 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL29103165 | 0.81 | ALDH1A1 (0.52) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL2754694 | 0.80 | CA12 (0.55) | KDM4EALDH1A1LMNAMAPTKMT2A | |
| SCHEMBL322015 | 0.80 | ALDH1A1 (0.50) | KDM4EALDH1A1MAPTKMT2ARAB9A | |
| SCHEMBL29648218 | 0.80 | CA12 (0.55) | KDM4EALDH1A1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-108368090-B | Compounds as immunomodulators | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | disclosed |
| US-10745382-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| EP-3362443-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017066227-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-20 | — | — | US | disclosed |
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | KDM4E 1574/4885ALDH1A1 1819/4885LMNA 1943/4885 |
| US-10745382-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | KDM4E 4249/4885ALDH1A1 1130/4885LMNA 4791/4885 |
| US-20170107202-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | KDM4E 4249/4885ALDH1A1 1130/4885LMNA 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.